12 completed, 2 recruiting, 1 active not recruiting, 1 terminated. 17 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 17 | Completed 12, Recruiting 2, Active not recruiting 1, Terminated 1, Unknown 1 |
| Phase 2 | 1 | Completed 1 |
Follow Valacyclovir: new trials by email Literature Review of Valacyclovir trials Research Report on Valacyclovir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA) Aglatimagene Besadenovec, Valacyclovir, Pembrolizumab - Non-squamous, Non-Small Cell Lung Cancer | Phase 3 | Recruiting | Candel Therapeutics, Inc. | 500 | 2026-06-15 | 2026-06-22 |
| Prenatal Treatment of Congenital Cytomegalovirus Infection With Letermovir Versus Valaciclovir Letermovir, Valacyclovir - Pregnant Women, CMV Infected Fetuses | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 46 | 2023-10-20 | 2026-03-31 |
| Ultrasound-Guided Thoracic Paravertebral Block With Steroid and Local Anesthetic for Acute Herpes Zoster: Effects on Pain Control and Prevention of Postherpetic Neuralgia Valacyclovir + Paracetamol (Acetaminophen) + Gabapentin (standard medical therapy), Ultrasound-guided thoracic paravertebral block (TPVB) with bupivacaine 0.25% + methylprednisolone 40 mg - Postherpetic Neuralgia | Phase 3 | Completed | Assiut University | 100 | 2023-03-15 | 2026-01-20 |
| Valacyclovir to Prevent Vertical Transmission of Cytomegalovirus After Maternal Primary Infection During Pregnancy Valacyclovir, Placebo - Congenital Cytomegalovirus Infection | Phase 2 / Phase 3 | Completed | Rabin Medical Center | 100 | 2015-11-01 | 2019-07-16 |
| A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia FV-100, valacyclovir - Shingles, Herpes Zoster | Phase 3 | Terminated | ContraVir Pharmaceuticals, Inc. | 237 | 2015-06-01 | 2017-12-22 |
| Phase III Study of ASP2151 in Herpes Zoster Patients ASP2151, valaciclovir - Herpes Zoster | Phase 3 | Completed | Maruho Co., Ltd. | 751 | 2013-08-01 | 2018-11-27 |
| Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer Aglatimagene besadenovec + valacyclovir, Placebo + valacyclovir - Prostate Cancer | Phase 3 | Active not recruiting | Candel Therapeutics, Inc. | 711 | 2011-09-01 | 2026-10-02 |
| Can Valacyclovir Attenuate Inflammation in Antiretroviral-Treated HIV-Infected Individuals With Herpes Simplex Virus Type 2? Valacyclovir, Placebo - Human Immunodeficiency Virus, Herpes Simplex | Phase 3 | Completed | University Health Network, Toronto | 60 | 2010-09-01 | 2016-05-12 |
| Can Valacyclovir Delay the Need for Initiation of Human Immunodeficiency Virus (HIV) Treatment in HIV-infected Individuals? valacyclovir, Placebo - HIV Infection, Herpes Simplex Type II | Phase 3 | Completed | University Health Network, Toronto | 202 | 2010-03-01 | 2018-03-06 |
| Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes Famciclovir, Valacyclovir, Placebo matching famciclovir - Genital Herpes | Phase 3 | Completed | Novartis Pharmaceuticals | 1179 | 2006-03-01 | 2011-06-30 |
| HSV-2 Suppression to Reduce HIV-1 Levels in HIV-1 Co-infected Persons Valacyclovir, Matching Placebo - HIV Infections, Herpes Simplex | Phase 3 | Completed | University of Washington | 20 | 2005-01-01 | 2013-08-22 |
| HSV-2 Suppression to Reduce HIV-1 Levels in HIV-1, HSV-2 Co-infected Men. valacyclovir, matching placebo - HIV Infection, Herpes Simplex | Phase 3 | Completed | University of Washington | 20 | 2003-08-01 | 2013-08-22 |
| Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation acyclovir, acyclovir sodium, valacyclovir - Cancer | Phase 3 | Completed | Fred Hutchinson Cancer Center | 2002-04-01 | 2010-09-21 | |
| Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir Valacyclovir, Placebo - Encephalitis | Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 91 | 2000-09-01 | 2012-06-12 |
| A Study of Valacyclovir as Treatment for Genital Herpes Simplex Virus in HIV-Infected Patients Valacyclovir hydrochloride - Herpes Simplex, HIV Infections | Phase 3 | Unknown | Glaxo Wellcome | 1999-06-01 | 2005-06-24 | |
| Valaciclovir to Prevent Transmission of Herpes Simplex Virus Valaciclovir - Herpes Simplex | Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 180 | 1997-08-01 | 2008-03-04 |
| A Study of Valacyclovir Hydrochloride in the Prevention of Life-Threatening Cytomegalovirus Disease in HIV-Infected Patients Valacyclovir hydrochloride, Acyclovir - Cytomegalovirus Infections, HIV Infections | Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 1200 | 2011-03-01 |
Herpes Simplex (7) · HIV Infections (5) · Herpes Genitalis (3) · Sexually Transmitted Diseases (3) · Acquired Immunodeficiency Syndrome (2) · Cytomegalovirus Infections (2) · Herpes Zoster (2) · Neuralgia, Postherpetic (2) · Recurrence (2) · Anus Diseases (1) · Blast Crisis (1) · Breast Neoplasms (1) · Burkitt Lymphoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Ovarian Epithelial (1)
National Institute of Allergy and Infectious Diseases (NIAID) (3) · Candel Therapeutics, Inc. (2) · University Health Network, Toronto (2) · University of Washington (2) · Assistance Publique - Hôpitaux de Paris (1) · Assiut University (1) · ContraVir Pharmaceuticals, Inc. (1) · Fred Hutchinson Cancer Center (1) · Glaxo Wellcome (1) · Maruho Co., Ltd. (1) · Novartis Pharmaceuticals (1) · Rabin Medical Center (1)
United States (9) · Canada (6) · United Kingdom (3) · Australia (2) · France (2) · Germany (2) · Peru (2) · Sweden (2) · Argentina (1) · Brazil (1) · Denmark (1) · Egypt (1) · Israel (1) · Italy (1) · Japan (1)
Connie Celum, MD, MPH (2) · Darrell HS Tan, MD FRCPC (2) · Sharon L Walmsley, MD FRCPC MSc (2) · Feinberg J (1) · Garrett Nichols, MD, MSC (1) · John Sullivan-Bolyai (1) · Keren Shahar-Nissan, Dr (1) · Maruho Co.,Ltd. Kyoto R&D Center (1)
PMID 17617198, PMID 18008230, PMID 18928378, PMID 19169140, PMID 19192993, PMID 23946220, PMID 25956891, PMID 32919517, PMID 42225101
N01AI30025 (1)